Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Immunosuppressants - GCC

GCC
  • In the GCC region, the revenue in the Immunosuppressants market is predicted to reach US$323.30m by 2024.
  • It is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of 15.30%, leading to a market volume of US$658.90m by 2029.
  • When compared globally, United States is expected to generate the highest revenue of US$35.47bn in 2024.
  • The market for immunosuppressants in the GCC is experiencing a steady growth due to the increasing prevalence of autoimmune diseases in the region.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

In-Scope

  • Drugs to suppress the immune response
  • Immunosuppressants to treat auto-immune diseases, such as psoriasis
  • Anti-rejection drugs

Out-Of-Scope

  • Multiple sclerosis drugs
  • Anti-rheumatic drugs
  • Immuno-oncology drugs
  • Antivirals
  • Antibiotics
  • Corticosteroids
  • HIV drugs
Immunosuppressants: market data & analysis - Cover

Market Insights report

Immunosuppressants: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The demand for immunosuppressants in the Gulf Cooperation Council (GCC) region has been on the rise in recent years.

    Customer preferences:
    The increase in demand for immunosuppressants in the GCC region can be attributed to the rising prevalence of autoimmune diseases and organ transplant surgeries. The region has a high prevalence of diseases such as rheumatoid arthritis, multiple sclerosis, and lupus, which require long-term treatment with immunosuppressants. In addition, the region has seen a rise in the number of organ transplant surgeries, which also require the use of immunosuppressants to prevent organ rejection.

    Trends in the market:
    The immunosuppressants market in the GCC region is expected to continue to grow in the coming years. This growth can be attributed to several factors, including an increasing number of transplant surgeries, a growing elderly population, and rising prevalence of autoimmune diseases. The market is also expected to benefit from the introduction of new and innovative drugs.

    Local special circumstances:
    One of the unique challenges facing the immunosuppressants market in the GCC region is the high prevalence of consanguineous marriages. This has led to a higher incidence of genetic diseases, which often require long-term treatment with immunosuppressants. In addition, the region has a high rate of obesity, which is a risk factor for several autoimmune diseases.

    Underlying macroeconomic factors:
    The GCC region has a rapidly growing population, which is expected to drive demand for healthcare services, including immunosuppressants. The region is also investing heavily in healthcare infrastructure, which is expected to improve access to healthcare services for its citizens. In addition, the region has a high per capita income, which means that patients are able to afford expensive treatments such as immunosuppressants.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Immunosuppressants: market data & analysis - BackgroundImmunosuppressants: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.